Table 1.
Study Characteristics (N = 13)
| Study | Cancer type | Age | No. of arms(number of participants in IG†/CG†) | Resilience measure | Resilience as primary outcome | Intervention type | CBT delivery; | Measurement time point |
|---|---|---|---|---|---|---|---|---|
| Cancer present (yes/no) | Gender | CBT format; | ||||||
| CBT no. of session; | ||||||||
| Cancer stage | CBT duration, weeks | |||||||
| Peihua Wu 2018-China [26] |
Breast cancer; Yes; Stage 0–3 |
Mean age: 51.2; Female (100%) |
2(20/20) | RS† | Yes | Psycho-educational interventions (PEIs)② | Face-to-face | Before the first chemotherapy session (T0) and at 2 weeks after the final chemotherapy session (T1) |
| Individual | ||||||||
| 6 sessions | ||||||||
| 6 weeks | ||||||||
| Kaina Zhou 019-China [27] |
Breast cancer; Yes; Stage 0–3 |
Mean age: 44.56; Female (100%); |
2(66/66) | CD-RISC† | Yes | Cyclic adjustment training② | Mobile device | Before the treatment (T0), immediately after the treatment (T1) |
| Individual | ||||||||
| 12 sessions | ||||||||
| 12 weeks | ||||||||
| Chuan Yan Lin 2020-China [28] |
Colon cancer; No; Stage 2–4 |
Mean age: 42; Males (68%); |
2(100/100) | CD-RISC† | Yes | Attention and interpretation therapy (AIT)① | Face-to-face | Before the treatment (T0), immediately after the treatment (T1) |
| Group | ||||||||
| 10 sessions | ||||||||
| 10 weeks | ||||||||
| Jiajia Zhang 2021-China [29] |
Pituitary adenoma; No; Stage 2–4 |
Mean age: 40 Male (55%); |
2(50/50) | CD-RISC† | Yes | Cognitive bias modification (CBM)① | Mobile device | Before the treatment (T0), immediately after the treatment (T1) |
| Individual | ||||||||
| 8 sessions | ||||||||
| 8 weeks | ||||||||
| Yulian Lei 2019-China [30] |
Prostate cancer; Yes; NR |
Mean age: 62.65; Male (100%); |
2(60/60) | CD-RISC† | Yes | Cognitive Behavior Intervention② | Face-to-face | Before the treatment (T0), immediately after the treatment (T1) |
| Individual | ||||||||
| 5 sessions | ||||||||
| 5 weeks | ||||||||
| Caitlin E. Loprinzi 2011-United States [31] |
Breast cancer; No; Stage 0–3 |
Mean age: 46; Female (100%); | 2(12/8) | CD-RISC† | No | Stress Management and Resiliency Training② | Face-to-face | Before the treatment (T0), immediately after the treatment (T1) |
| Individual | ||||||||
| 2 sessions | ||||||||
| 12 weeks | ||||||||
| Yao Zhang 2023-China [32] |
Breast cancer; Yes; NR; |
Mean age 47.37; Female (100%); |
2(49/49) | CD-RISC† | No | Family‑centered positive psychological intervention② | Face-to-face |
Outcome measures compared at baseline (T1), immediately after the intervention (T2), and at 1-month follow-up (T3) |
| Couple | ||||||||
| 4 sessions | ||||||||
| 4 weeks | ||||||||
| Weiping Yang 2021-China [33] |
Malignant glioma patients; Yes; Stage 2–4; |
Mean age (53.1 ± 10.6); Male (50%); |
2(30/30) | CD-RISC† | No | Cognitive Behavior Intervention① | Face-to-face | Before the treatment (T0), immediately after the treatment (T1) |
| Individual | ||||||||
| 6 sessions | ||||||||
| 6 weeks | ||||||||
| Na Zhang 2021-China [34] |
Malignant lymphoma patients; Yes; Stage 2–4; |
Mean age (52.81 ± 9.64); Male (70.63%); |
2(72/88) | CD-RISC† | Yes | Cognitive Behavior Intervention① | Mobile device | Before the treatment (T0), immediately after the treatment (T1) |
| Group | ||||||||
| 8 sessions | ||||||||
| 4 weeks | ||||||||
| Qiaoping Wang 2018-China [35] |
Esophageal cancer patients; No; Stage 0–3; |
Mean age (54.4 ± 14.1); Male (56.94%); |
2(36/36) | CD-RISC† | No | Cognitive Behavior Intervention① | Face-to-face | Before the treatment (T0), immediately after the treatment (T1) |
| Individual | ||||||||
| 6 sessions | ||||||||
| 2 weeks | ||||||||
| Kemei Wu 2020-China [26] |
Mixed cancer; No; Stage 0–3; |
Mean age (54.03 ± 4.87); Male (57%); |
2(50/50) | CD-RISC† | No | Cognitive Behavior Intervention① | Face-to-face | Before the treatment (T0), immediately after the treatment (T1) |
| Group | ||||||||
| Not clearly | ||||||||
| Not clearly | ||||||||
| Juan Wang 2022-China [36] |
Thyroid cancer; No; Stage 0–3; |
Mean age (51.78 ± 8.12); Male (29.31%); |
2(26/27) | CD-RISC† | No | Cognitive Behavior Intervention① | Face-to-face | Before the treatment (T0), immediately after the treatment (T1) |
| Group | ||||||||
| 8 sessions | ||||||||
| 8 weeks | ||||||||
| Fatemeh Faghani 2022-Iran [37] |
Mixed cancer; No; NR; |
Mean age: 37.9; Female (60%); |
2(15/15) | CD-RISC† | No | Mindfulness-based supportive psychotherapy② | Face-to-face | Before the treatment (T0), immediately after the treatment (T1) and in a 3-month follow-up (T2) |
| Individual | ||||||||
| 6 sessions | ||||||||
| 6 weeks |
Abbreviations: †CD-RISC: Conner–Davison Resilience Scale;
†RS: Resilience Scale;
†IG: intervention group;
†CG: control group;
① Traditional CBT; ② Contemporary CBT